Robert L. Coleman, MD, FACOG, FACS | Authors

Articles

Patients With Ovarian Cancer Likely to Respond to Rucaparib Using Tumor Genetic Analysis

June 10, 2015

Robert L. Coleman, MD, FACOG, FACS, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the results of the ARIEL2 trial, a phase II study to identify patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis.

Impact of Bevacizumab in Ovarian Cancer

April 29, 2015

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses a study which examined the impact of bevacizumab in ovarian cancer.